Gemigliptin (tartrate)

Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE) -related diabetic complications[1][2].

Product Specifications

CAS Number

[1374639-74-3]

Product Name Alternative

LC15-0444 (tartrate)

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Dipeptidyl Peptidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/gemigliptin-tartrate.html

Purity

99.52

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)[C@H](O)[C@@H](O)C(O)=O.O=C1N(C[C@@H](N)CC(N2CCC3=C(C(F)(F)F)N=C(C(F)(F)F)N=C3C2)=O)CC(F)(F)CC1

Molecular Formula

C22H25F8N5O8

Molecular Weight

639.45

Precautions

H315, H319, H335

References & Citations

[1]Jung E, et al. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. Eur J Pharmacol. 2014 Dec 5;744:98-102.|[2]Kim SH, et al. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Eur J Pharmacol. 2016 Oct 5;788:54-64.